NCT06789445View on ClinicalTrials.gov

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2030

Conditions
Primary Photoreceptor DiseaseRetinitis Pigmentosa (RP)Usher SyndromeCone-Rod DystrophyInherited Retinal Disease (IRD)Rod-Cone DystrophyRod-Cone DiseaseCone-Rod DiseaseRetinal Degeneration
Interventions
BIOLOGICAL

OpCT-001

Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs).

BIOLOGICAL

OpCT-001

Cell therapy product composed of photoreceptor precursor cells derived from human iPSCs.

Trial Locations (3)

33136

RECRUITING

University of Miami, Bascom Palmer Eye Institute, Miami

53705

RECRUITING

University of Wisconsin, Madison

75231

RECRUITING

Retina Foundation of the Southwest, Dallas

Sponsors
All Listed Sponsors
lead

BlueRock Therapeutics

INDUSTRY

NCT06789445 - A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) | Biotech Hunter | Biotech Hunter